Document is current
Any future updates will be listed below
-
Authors
Unger, Lukas W. http://orcid.org/0000-0002-8423-2268
Forstner, Bernadette
Schneglberger, Stephan
Muckenhuber, Moritz
Eigenbauer, Ernst
Bauer, David http://orcid.org/0000-0002-9363-8518
Scheiner, Bernhard
Mandorfer, Mattias http://orcid.org/0000-0003-2330-0017
Trauner, Michael
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
- License Information
-
More Information
Article History
Received: 28 November 2018
Accepted: 10 July 2019
First Online: 12 August 2019
Competing Interests
: Lukas Unger, Bernadette Forstner, Stephan Schneglberger, Moritz Muckenhuber, Ernst Eigenbauer, Bernhard Scheiner have no conflicts of interest with regard to the manuscript. David Bauer has received a travel grant from Gilead. Mattias Mandorfer has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W. L. Gore & Associates, and Janssen. Thomas Reiberger has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, W. L. Gore & Associates, and MSD and has received research funding from AbbVie, Boehringer Ingelheim, Gilead, MSD, Phenex Pharmaceuticals, and Philips. Michael Trauner has served a speaker for BMS, Falk Foundation, Gilead and MSD; advisory boards for Albireo, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. He is also co-inventor of patents on the medical use of norUDCA filed by the Medical University of Graz.
